Gefitinib is a specific inhibitor that targets epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF), and PDGF, clinically applied for non-small cell lung cancer (NSCLC).135. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.